Kevin Grogan has been writing about pharmaceuticals for over twenty years in roles that have included online editor for PharmaTimes. After four years freelancing, which involved writing for all the principal titles in the sector, as well as consultancy work with major pharmaceutical companies, he joined Scrip as Managing Editor, Europe, Commercial in the summer of 2017.
Covering all aspects of the pharma industry, Kevin has interviewed pretty much all the leading figures in the sector, both in the UK and globally. A regular attendee at financial and medical conferences worldwide (and moderating at some), he has also appeared on BBC television and radio, ITV and Channel 4 to discuss events in the pharmaceutical industry.
Fluent in Spanish, he previously worked as a journalist on rock/pop music publications, was chief sub editor at the Catholic weekly newspaper The Universe and also contributed articles to the likes of The Independent and the Manchester Evening News on football.
Latest From Kevin Grogan
The head of the German group's pharma BD team tells Scrip that Bayer has created a system which allows it to move quickly when sealing partnerships, as seen with the KaNDy buy on 11 August.
Her experience in banking and consultancy helped C4XD strategy chief Bhavna Hunjan to build a team that drives corporate development through partnerships, with a focus on attractive preclinical data packages to out-license to pharmaceutical companies.
Bayer is paying $425m upfront to acquire KaNDy Therapeutics, whose CEO tells Scrip that the German group was always the preferred partner due to its long-standing commitment to women’s health.
Attempts at developing an effective therapy for PWS, and the abnormal desire for food associated with the rare disorder, have been fruitless but Levo Therapeutics' enthusiasm for LV-101 remains high, despite a Phase III setback.
Tecentriq is the only checkpoint inhibitor to get approval for first-line TNBC but failure in a second study for that indication will encourage rival Merck & Co with Keytruda nearing approval.
Despite COVID-19, Horizon Therapeutics has pulled off a spectacularly successful launch of its thyroid eye disease therapy, Tepezza, thanks to pre-commercial activities that led to a high level of initial patient and prescriber awareness, and market access teams securing a decent reimbursement rate.